Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q…
IronSight AI and Fast Iron Partner to Bring AI-Powered Inventory Capture to Caterpillar, Komatsu and Volvo Equipment Dealers
WCDPQ Plans South American Expansion in 2027, Including 30 New Positions